EXECUTIVE ENGAGEMENTS
POOL
3123
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
562
Interactions with Platform & by Email
PARTICIPANTS
94
Unique # Participated
VALIDATIONS
27
Responses Validated*
COMPANIES
48
Responses Validated*
* Login for a full stack data experience
DATE
JUL 2022
TABLES
306
PAGES
605
EDITION
9
PRICE
USD 5450
CODE
MCP16923
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
Global Lung Cancer Diagnostics Market to Reach $3.4 Billion by 2026
Lung cancer represents the leading cause of cancer deaths globally. The disease is categorized into Small-cell Lung Cancer (SCLC) and Non-small cell lung cancer (NSCLC), with the latter constituting for about 80-85% of cases. Early detection of lung cancer, for both NSCLC and SCLC, is taking increased precedence globally which in turn spurs demand for lung cancer diagnostics. Amid the COVID-19 crisis, the global market for Lung Cancer Diagnostics is projected to reach US$3.4 Billion by 2026, registering a compounded annual growth rate (CAGR) of 7.6% over the analysis period. The United States represents the largest regional market for Lung Cancer Diagnostics, and is projected to reach US$843.4 Million by 2026. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 11% over the analysis period.
The market is driven by rising incidence of lung cancer, increasing awareness levels about the symptoms and the seriousness of the condition, technological advancements, and new product launches. Increased focus on the development of lung cancer-specific biomarkers bodes well for the market growth. The ability of such diagnostic tools to enable personalized treatment for lung malignancies fuels market growth. The rapid rise in the number of smokers in developing regions also represents an important growth driver for the lung cancer diagnostics market. Significant advancements in diagnosis and early detection are transforming the lung cancer treatment landscape. High prevalence rate of Non-Small Cell Lung Cancer (NSCLC) is especially driving interest in the diagnostic value offered by liquid biopsies. Liquid biopsies, which utilize cell-free tumor DNA (cfDNA) and tumor-derived exosomes to detect mutations, will play a key role in precision medicine in the coming years.
HIGHLIGHTS & REPORT INDEX
What`s New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Global Lung Cancer Diagnostics Market to Reach $3.4 Billion by 2026
Lung cancer represents the leading cause of cancer deaths globally. The disease is categorized into Small-cell Lung Cancer (SCLC) and Non-small cell lung cancer (NSCLC), with the latter constituting for about 80-85% of cases. Early detection of lung cancer, for both NSCLC and SCLC, is taking increased precedence globally which in turn spurs demand for lung cancer diagnostics. Amid the COVID-19 crisis, the global market for Lung Cancer Diagnostics is projected to reach US$3.4 Billion by 2026, registering a compounded annual growth rate (CAGR) of 7.6% over the analysis period. The United States represents the largest regional market for Lung Cancer Diagnostics, and is projected to reach US$843.4 Million by 2026. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 11% over the analysis period.
The market is driven by rising incidence of lung cancer, increasing awareness levels about the symptoms and the seriousness of the condition, technological advancements, and new product launches. Increased focus on the development of lung cancer-specific biomarkers bodes well for the market growth. The ability of such diagnostic tools to enable personalized treatment for lung malignancies fuels market growth. The rapid rise in the number of smokers in developing regions also represents an important growth driver for the lung cancer diagnostics market. Significant advancements in diagnosis and early detection are transforming the lung cancer treatment landscape. High prevalence rate of Non-Small Cell Lung Cancer (NSCLC) is especially driving interest in the diagnostic value offered by liquid biopsies. Liquid biopsies, which utilize cell-free tumor DNA (cfDNA) and tumor-derived exosomes to detect mutations, will play a key role in precision medicine in the coming years.
By region, developed economies account for a significant share of the lung cancer diagnostics market. The US holds the largest market share, owing to key factors such as growing patient awareness, high market penetration of innovative and technologically advanced products, and rapid urbanization and industrial development. The increasing prevalence of lung cancer in the region driven by increase in risk factors like cigarette smoking, exposure to second hand smoke, occupational exposure to cancer causing chemicals, has spurred the development of innovative and advanced diagnostic solutions. Growth in Asia-Pacific region is fueled by key growth drivers, such as rising awareness of symptoms of lung cancer, emerging demand for advanced lung cancer diagnostic tools, improving healthcare infrastructure, and large base of patients with unmet clinical needs. Rising healthcare expenditure and the presence of a large patient pool in countries like India and China is expected to unfurl significant growth opportunities.
The market for molecular tests is forecast to grow the fastest over the analysis period. Molecular tests are generally done on tissue from biopsy or surgery, as well as on blood taken from a vein. The rapid pace of advancements and innovations in the area of molecular diagnostic technology are leading to the development and launch of several new types of diagnostic test techniques, aiding use of molecular tests for lung cancer diagnosis. The use of molecular tests for lung cancer diagnosis also facilitates in developing personalized treatments. Sustained increase in investments into R&D initiatives for developing biomarker-based molecular testing for lung cancer detection will also support segment growth.
SELECT PLAYERS
Abbott Diagnostics - Core Laboratory; Dr Lal PathLabs; F. Hoffmann-La Roche AG; Illumina Inc.; Myriad Genetics Inc.; NanoString Technologies; NeoGenomics Laboratories Inc.; PlexBio Co., Ltd.; QIAGEN GmbH; Quest Diagnostics; Thermo Fisher Scientific Inc.
SEGMENTS
» Test (Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy, and Other Tests) » Type (Non-Small-Cell Lung Cancer (NSCLC), and Small-Cell Lung Cancer (SCLC) » and End-Use (Hospital Laboratories, Cancer Research Institutes, and Other End-Uses)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Early Detection of Lung Cancer Takes Precedence, Driving the Demand for Lung Cancer Diagnostics |
| Non-small Cell Lung Cancer - The More Prominent of the Two Lung Cancer Types |
| Imaging Tests Segment Dominates the Market, Molecular Tests Category to Witness High Growth |
| US Leads the Lung Cancer Diagnostics Market, Asia-Pacific to Witness Fastest Growth |
| Lung Cancer Diagnostics – Global Key Competitors Percentage Market Share in 2022 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Agilent Technologies Inc. (USA) |
| F. Hoffmann-La Roche Ltd. (Switzerland) |
| Illumina, Inc. (USA) |
| NeoGenomics Laboratories, Inc. (USA) |
| QIAGEN N.V. (The Netherlands) |
| Thermo Fisher Scientific, Inc. (USA) |
| Veracyte (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Early Diagnoses |
| Age-Standardized Lung Cancer Rates for Select Countries |
| Age-Standardized Lung Cancer Rates in Men for Select Countries |
| Age Standardized Lung Cancer Rates in Women for Select Countries |
| Lung Cancer-Specific Biomarkers to Spur Market Growth |
| Select Lung Cancer Biomarkers |
| New Potential Biomarker for Early Stage Lung Cancer Identified in a Recent NCI Study (2019) |
| Advancements and Research Initiatives in Lung Cancer Diagnostics Space |
| EFIRM Test for Detection of Lung Cancer-related EGFR Mutations in NSCLC Patients |
| A Glance at Select Recent Launches of Lung Cancer Diagnostic Tests |
| New Product Launches/Approvals in the Lung Cancer Diagnostics |
| Recent Approvals |
| Liquid Biopsies Grow in Value as a Diagnostic Tool Supporting Therapy Decisions in NSCLCs |
| Effervescent Rate of New Innovations & Product Development Will Make Liquid Biopsy a Readily Available Option for Patients in the Coming Years |
| High Cigarette Consumption/Rise in Prevalence of Smoking Increases the Incidence of Lung Cancer |
| Cigarette Consumption Per Year Per Person Across Select Countries: 2016 |
| Top 15 Countries with the Highest Smoking Rates: 2015 |
| Increasing Number of Awareness Programs for Lung Cancer and Symptoms |
| Growing Availability of Government/Private Funding for R&D to Develop Lung Cancer Diagnostics |
| Table: National Cancer Institute Research Funding for Lung Cancer in US$ Million for the Years 2014 through 2017 |
| Aging Demographics & Unhealthy Lifestyles Raise the Risk of Cancer |
| Cancer Prone Sites based on Age |
| Table: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Lung Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Imaging Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Sputum Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Sputum Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Sputum Cytology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Molecular Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Molecular Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Molecular Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Small-Cell Lung Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Small-Cell Lung Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Small-Cell Lung Cancer (SCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hospital Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cancer Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| Lung Cancer Stats |
| US Lung and Bronchus Cancer New Cases by Gender: 2019E |
| US Lung and Bronchus Cancer Deaths by Gender: 2019E |
| Incidence Rates* for Lung and Bronchus Cancer by Gender, 2011-2015 |
| Death Rates* for Lung and Bronchus Cancer by Gender in the US, 2012-2016 |
| Incidence Rates for Lung and Bronchus Cancer by Race/Ethnicity, 2011-2015 |
| Reimbursement and Insurance Coverage for Lung Cancer Screening in the US |
| CY 2019 Medicare Physician Fee Payment Levels for Low Dose CT Scan (LDCT) Screening |
| CY 2019 Hospital Outpatient Prospective Payment System (HOPPS) Payment Levels for Low Dose CT Scan (LDCT) Screening |
| Oncimmune’s EarlyCDT Lung to be commercialized in the US by Biodesix (2019) |
| Market Analytics |
| USA Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| JAPAN |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| CHINA |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| China Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| China Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| EUROPE |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Lung Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| FRANCE |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| France Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| France Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| GERMANY |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| TABLE: UK Age-standardised Rate (per 100,00) of Lung Cancer Cases by Gender: 1980-2035P |
| UK Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| SPAIN |
| Spain Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Spain Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Spain Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| RUSSIA |
| Russia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Russia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Russia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Lung Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| AUSTRALIA |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E) |
| Australia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Australia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Australia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| INDIA |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E) |
| Rise in Incidence of Lung Cancer in India |
| Table: New Cancer Cases in India by Site: 2018 |
| India Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| India Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| India Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| SOUTH KOREA |
| South Korea Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| South Korea Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| South Korea Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| LATIN AMERICA |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E) |
| Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Lung Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027 |
| Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| ARGENTINA |
| Argentina Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Argentina Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Argentina Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| BRAZIL |
| Brazil Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Brazil Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Brazil Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| MEXICO |
| Mexico Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Mexico Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Mexico Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| REST OF LATIN AMERICA |
| Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| MIDDLE EAST |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E) |
| Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Lung Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027 |
| Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| IRAN |
| Iran Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Iran Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Iran Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| ISRAEL |
| Israel Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Israel Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Israel Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| SAUDI ARABIA |
| Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| UNITED ARAB EMIRATES |
| UAE Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| UAE Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| UAE Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| REST OF MIDDLE EAST |
| Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| AFRICA |
| Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E) |
| Africa Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2021 & 2027 |
| Africa Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2021 & 2027 |
| Africa Recent Past, Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 48 (including Divisions/Subsidiaries - 48) |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com